Navigation Links
Stem Cell Innovations to Provide Research and Assay Services to Agennix.
Date:3/2/2010

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors
'/>"/>

SOURCE Stem Cell Innovations, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Marrone Bio Innovations Announces Two New Executive Appointments
2. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
3. The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009
4. Marrone Bio Innovations Named an IC20 Company
5. Glycos Biotechnologies, Inc. Selected to Present at Alternative Energy Innovations 2009
6. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 27, 2009 to Discuss Third Quarter 2009 Results
7. The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations
8. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
9. Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
10. Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
11. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Virobay, Inc. today announced ... has reached an important milestone, as Virobay has now ... a selective cathepsin S inhibitor.   The ... randomized, placebo-controlled study designed to evaluate the safety, tolerability, ... healthy adults. "The initiation of this Phase ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... EASTON, Mass. , May 23, 2013 ... today announced that the Company will host a teleconference ... to provide a business update. The teleconference information is ... Time: 11:00 a.m. Eastern Daylight Time (EDT) ... ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... 28 Endo Pharmaceuticals Inc. (Nasdaq: ENDP ... financial results on February 27, 2009 and will ... ET that day to discuss these results. David ... Wysenski, Chief Operating Officer and Blaine Davis, Vice President, ...
... the Swiss,pharmaceutical group Helsinn announced the acquisition, of ... in,Bridgewater, New Jersey, for an undisclosed amount. , ... US-based R&D and commercial operation represents,attainment of one ... are,thrilled at this very important opportunity to increase ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... call and webcast on,Wednesday, February 18, at 5:00 p.m. ET ... results. , , U.S. / Canada Dial-in ... 617.213.8835, Participant Code: 35749059, ...
Cached Biology Technology:Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009 2Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 2Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2
(Date:5/23/2013)... Inside the natural history museums of the world are ... and beetles to flowers, mushrooms and grasses, all stacked, ... The rich and diverse collections could be critical to ... face of a growing human footprint if only ... project, brought to life with the help of a ...
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... Bacillus anthracis, the causative agent of anthrax, has been ... Drug Administration (FDA). The test, known as the Gamma ... Army Medical Research Institute of Infectious Diseases (USAMRIID) to ... specimens. The original form of the Gamma Phage Assay ...
... Scientists at The Scripps Research Institute have solved the ... TLR3, an acronym for Toll-like receptor three. In an ... described as a large horseshoe-shaped coil composed of 23 ... TLR3 that have never been seen before, an essential ...
... anthracis, the causative agent of anthrax, has been cleared ... Administration (FDA). The test, known as the Gamma Phage ... Medical Research Institute of Infectious Diseases (USAMRIID) to improve ... The original form of the Gamma Phage Assay was ...
Cached Biology News:'Mad cow' proteins successfully detected in blood 2'Mad cow' proteins successfully detected in blood 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4Anthrax test, developed by army and CDC, receives FDA approval 2Anthrax test, developed by army and CDC, receives FDA approval 3
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
HSPBP1 Antibody...
Biology Products: